A Study on Spirometric Evaluation in Patients with Diabetes Mellitus

Authors
Dr Tanzeem.S*1, Dr Ramakrishna Rao.M2, Dr Sheik Mohammed Raja3

*1, 3Post Graduate, Department of General Medicine, Rajah Muthiah Medical College and Hospital, Annamalai University, Annamalai Nagar – 608002

2Professor, Department of General Medicine, Rajah Muthiah Medical College and Hospital, Annamalai University, Annamalai Nagar – 608002

Corresponding Author
Dr Tanzeem.S
Post Graduate, Department of General Medicine, Rajah Muthiah Medical College and Hospital, Annamalai University, Annamalai Nagar – 608002

Abstract
The prevalence of diabetes mellitus is on a rising trend. Though great attention has been centered on the chronic complications like retinopathy, nephropathy, neuropathy and the macrovascular complications, the pulmonary complications have been poorly characterised. The aim of the present study was to assess the effects of chronic hyperglycemia on lung function, focusing on mechanical aspects of lung dysfunction with the help of spirometry. These complications might have a significant impact on the quality of life of the patients. This study showed reduced lung function in patients with diabetes, showing a restrictive pattern of lung involvement. Diabetes duration seems a more important influence than the glycaemic control.

Keywords: Diabetes Mellitus, Spirometry.

Introduction
Diabetes mellitus is a growing epidemic in the world. Nearly 70% of the people with diabetes live in developing countries; the largest numbers are in the Indian subcontinent (65.1 million) and China. The largest numbers with diabetes are in the 40 to 59 age groups (132 million, in 2010) which is expected to rise further. The prevalence of diabetes has risen from 30 million in 1985 to 382 million in 2013. It is estimated that the prevalence may rise to 592 million by the year 2035 according to current trends.1

Diabetes mellitus affects many organ systems and are the cause for the majority of the mortality and morbidity associated with the disease. Chronic complications are divided as vascular and nonvascular complications. The vascular complications are divided as micro and macrovascular complications. The risk of chronic complications increases with the duration of the disease and the glycemic control. Since type 2 DM has a long asymptomatic period many patients present with complications at the time of diagnosis. Airflow limitation and reduction in lung volumes are likely to be chronic complications of diabetes mellitus. This study hypothesises that the lung is also a target organ in diabetes.2 The pulmonary function is assessed using spirometry.
Materials and Methods

Diabetic patients, who are on treatment for more than 3 months were randomly selected from the outpatient department. Their consent was taken. Screening of the patients was done for exclusion criteria and 100 patients were included in the study. A detailed history including the duration and treatment along with examination of the respiratory system was carried out. Age, height (in cms), weight (in kg), body mass index (wt in kg/ht in m²) was recorded. All the findings were recorded in the proforma. Fasting blood sugar, Post prandial blood sugar, HbA1c levels were measured for all the study subjects.

Smokers, those with previous history of lung disease, those with signs and symptoms of respiratory infections at the time of test, Obese person (BMI > 30 kg/m²), those with neuromuscular disease or thoracic cage abnormalities were all excluded from the study.

Spirometry was performed in all the study subjects and the variables recorded were forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and the ratio of FEV1/FVC.

Results

Among the 100 diabetic subjects, most of them belonged to the age group of 41-50 years. Our study showed that all the spirometric variables, that is, FVC and FEV1 were reduced to less than 80% of the predicted values. PEFR was also reduced. The ratio of FEV1/FVC was within normal limits suggestive of a restrictive pattern. [Table -2,3]

Table 1: Age distribution

| Age group     | No | %  |
|---------------|----|----|
| Upto 40 yrs   | 12 | 12.0 |
| 41-50 yrs     | 56 | 56.0 |
| 51-60 yrs     | 32 | 32.0 |
| Total         | 100| 100.0 |
| Range         | 20-60 yrs |
| Mean          | 46.53 yrs |
| SD            | 8.58 yrs |

Table 2: Observed spirometric results

| Variable             | Mean | SD  |
|----------------------|------|-----|
| FVC                  | 2.31 | 0.60 |
| FEV1                 | 1.78 | 0.59 |
| FEV1/FVC Ratio       | 76.17| 9.15 |
| PEF                  | 399.51| 77.71 |

Table 3: % predicted PFT in diabetic subjects

| Variable             | Mean | SD  |
|----------------------|------|-----|
| FVC                  | 75.82| 14.96 |
| FEV1                 | 70.45| 19.20 |
| FEV1/FVC Ratio       | 91.82| 10.97 |
| PEF                  | 84.31| 11.53 |

Graph -1: % predicted PFT in diabetic subjects

Discussion

The results of the present study indicate that diabetes is associated with reduced lung function. This study is in accordance with many previous studies which showed reduced pulmonary function in diabetic patients.[5-9]

Timothy Davis et at conducted a study on pulmonary function test in 421 European subjects with type 2 diabetes. The pulmonary function parameters were reduced by an average of approximately 10%. The lowest values were observed in smokers, both current and ex-smokers.[10]

Uchida et al found that the pulmonary diffusion capacity was decreased in patients with diabetes. A perfusion defect in ventilation perfusion scintigrams was observed.[11]

Ehrlich et al showed that patients with diabetes were at increased risk of pulmonary conditions like Asthma, COPD, fibrosis and pneumonia.[12]

The mechanism by which impaired glycemic control may lead to a reduction in lung function is
uncertain, though it has been suggested that the increased systemic inflammation associated with diabetes \[^{13}\] may result in pulmonary inflammation \[^{14}\] as well, and hence, it can cause air way damage\[^{15}\]. Moreover, secondary reduction in the antioxidant defence of lung and increased susceptibility to environmental oxidative insults results in the subsequent loss of lung function\[^{16}\] and ultimately, lung damage. The thorax and lungs are rich in collagen and elastin. Stiffening of lung parenchyma can occur because of nonenzymatic glycosylation of these structural compounds. This may lead to restrictive pattern.\[^{2}\]

In our study, more than 50% of the diabetic patients had a restrictive pattern of lung involvement with <80% predicted values of FVC and FEV1, and the ratio of FEV1/FVC was >70% of predicted values.

**Conclusion**

Diabetes Mellitus being a systemic disease, also affects lungs causing restrictive type of pulmonary function tests probably because of glycosylation of connective tissues, reduced pulmonary elastic recoil and inflammatory changes in lungs. It is advisable therefore, that diabetic patients must undergo periodic spirometry tests to assess the severity of lung function impairment. Additional research is required to identify pathophysiologic mechanisms and to determine clinical significance of this association.

**Bibliography**

1. Longo, Fauci, Kasper, Hauser, Jameson, Loscalzo Harrison’s principles of internal medicine 19th edition.
2. Sandler Malcom – Is the lung a target organ in diabetes mellitus? Arch Internal Medicine 1990; 150:1385-88.
3. Trinder, P. Deter mination of glucase in blood using grocase oxidose with an alternative oxygen acceptor. Ann Clin Biochem. 1969;6:24-27.
4. Nathan DM. A1c-Derived Average Glucose Study Group. Translating the A1c assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473–78. [PMID: 18540046].
5. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes, the fremantle diabetes study. Diabetes Care. 2004;27:752–7. [PubMed]
6. Asanuma Y, Fujiya S, Ide H, Agishi Y. Characteristics of pulmonary function in patients with diabetes mellitus. Diabetes Res Clin Pract. 1985;1:95–101. [PubMed]
7. Lange P, Groth S, Kastrup J, Mortensen J, Appleyard M, Nyboe J, et al. Diabetes mellitus, plasma glucose and lung function in a cross sectional population study. Eur Respir J. 1989;2:14–9. [PubMed]
8. Barrett-Conor E, Frette C. NIDDM, impaired glucose tolerance, and pulmonary function in older adults. Diabetes Care. 1996; 19: 1441-4. [PubMed]
9. Davis TM, Knuiman M, Kendall P, Vu H, Davis WA. Reduced pulmonary function and its association in type 2 diabetes: The fremantle diabetes study. Diabetes Res Clin Pract. 2000; 50:153–9. [PubMed]
10. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study Timothy M.EDavis Matthew Knuiman PeterKendall HienVu Wendy ADAvis Diabetes Research and Clinical Practice, volume 50,issue 2,October 2000
11. Uchida K, Takahashi K, Aoki R, Ashitaka T. Ventilation-perfusion scintigram in diabetics. Ann Nucl Med. 1991;5:97–102. [PubMed]
12. Ehrlich SF, Quesenberry CP, Vanden Eeden SK, Shan J, Ferrara A. Patients diagnosed with diabetes are at increased risk for asthma, COPD, pulmonary fibrosis and pneumonia but not lung cancer. Diabetes Care. 2010; 33:55–60. [PMC free article] [PubMed]
13. Arnalich F, Hernanz A, Lopez-Maderuelo D. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Horm Metab Res 2000;32:407–12.
14. Walter R, Beiser A, Givelber R. The association between glycemic state and lung function: the Framingham heart study. Am J Respir Crit Care Med 2003;167:911–6.
15. Cirillo D, Agrawal Y, Cassano P. Lipids and pulmonary function in the third national health and nutrition examination survey. Am J Epidemiol 2002;155:842–8.
16. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–20.